Loading…

Roche Holding LtdRO.SWCompetitor analysis, valuation and peers

Switzerland · CHF·Health Care›Pharmaceuticals: Major

Swiss pharmaceutical and diagnostics leader, developing cancer, immunology, and neuroscience drugs alongside lab and diagnostic testing equipment.

≈ A Swiss Pfizer/Danaher hybrid (pharma + diagnostics)Momentum strong 76
Mkt cap
$381B
US dollars, full cap
Free float
28%
of shares outstanding
$/day
$13.4M
20-day average traded
Fwd P/E
19.9×
forward earnings
ROIC−WACC
+18.4 pp
WACC 5.4%
Hurdle
+1 pp
Req g minus delivered
Official | Implied
AA / AA
agencies · bond market
Next earnings
71 days
28 Jan 2027
Close · CHFCHF 407.60
1D-0.8%
1W-0.9%
1M+3.0%
3M+7.4%
6M+21.2%
YTD+21.6%
1Y+35.8%
ATR %1.7%
52w lowhigh2.4% off high

What Roche does

Swiss pharmaceutical and diagnostics leader, developing cancer, immunology, and neuroscience drugs alongside lab and diagnostic testing equipment.

Two businesses: prescription medicines, the larger, and diagnostics, which places testing machines with laboratories and then sells the chemicals used in every test, a recurring stream. Genentech is its US biotech arm. The Hoffmann and Oeri founding families hold the voting shares.

In one line: A Swiss Pfizer/Danaher hybrid (pharma + diagnostics).

Products and services

  • Oncology drugs
  • Immunology/neuroscience drugs
  • Diagnostics (lab testing systems)
  • Genentech (US biotech, majority-owned)

Customers

  • Hospitals and oncology clinics
  • Diagnostic laboratories
  • Patients via prescribers

Where it sits in the supply chain

  • Healthcare
  • Pharmaceuticals & diagnostics
  • Drug discovery/development + in-vitro…

What could go right

  • New oncology drug launches
  • Diagnostics demand growth

What could go wrong

  • Patent cliffs on key drugs
  • Drug pricing/reimbursement pressure

Moat: wide (IP / patents, scale, regulatory licence). Deep oncology drug patent portfolio plus a diagnostics business few pharma peers also operate at scale.

Headquarters: Basel, Switzerland · Founded: 1896 · Employees: 112,774

Named competitors

Roche at a glance

Size Roche (RO.SW) is a Switzerland Health Care company (Pharmaceuticals: Major) with a market value of $381B, the largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 407.60 on 18 Nov 2026.

Performance Over six months the shares gained 21.2%, against +13.0% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 6th highest of 14 in its peer set.

Growth Revenue fell 1.1% over the last twelve months (peer median +5.7%); the operating margin is 30.6% (peer median 30.4%).

Valuation It trades at 19.9× forward earnings against a peer median of 16.4× (4th most expensive of 14).

Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 18.4 points above its cost of capital (5.4% WACC).

Credit Roche has 20 bonds outstanding ($17.9B), rated AA by the agencies and trading like AA at a weighted spread of 62 bp.

Next results Next results expected around 28 Jan 2027 (exchange calendar; dates can move).

Relative performance

10011012021 May 202621 Aug 202618 Nov 2026RO.SW 121Peer median 112
Six months, rebased to 100: Roche against the median of its 13 peers (local-currency closes).

Roche financials

Reported figures in CHF; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCHF 60.9BCHF 61.5BCHF 60.5BCHF 58.7BCHF 63.3B
Revenue growth—+2%+3%-7%—
Gross profitCHF 44.3BCHF 45.2BCHF 44.5BCHF 42.9BCHF 44.4B
EBITDACHF 22.1BCHF 22.7BCHF 21.7BCHF 19.8BCHF 22.0B
Net incomeCHF 12.3BCHF 12.9BCHF 8.28BCHF 11.5BCHF 12.4B
Free cash flowCHF 14.8BCHF 14.1BCHF 15.7BCHF 11.8BCHF 14.4B
Capital expenditureCHF 5.62BCHF 5.78BCHF 5.01BCHF 4.65BCHF 4.55B
Total debtn/aCHF 33.2BCHF 36.4BCHF 30.8BCHF 26.5B

Quarterly statements and history in the cockpit →

Roche competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%0%+10%MRKABBVNOVNAZNJNJNOVO-BPFEVRTXBMYSANLLYGSKREGNRO.SW6-month return →1-month return →
Up and to the right = strong over both horizons. Roche is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%10×20×30×MRKABBVNOVNAZNJNJNOVO-BPFEVRTXBMYSANLLYGSKREGNRO.SWRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Roche is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%-10%0%10%20%MRKABBVNOVNAZNJNJNOVO-BPFEVRTXBMYSANLLYGSKREGNRO.SWGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Roche is the large dot.

Roche competitors and peer comparison

Head to head with its named competitors (RO.SW vs NOVN.SW vs PFE vs MRK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Roche RO.SW$381B+21%-1%31%19.9×1.7%
Novartis NOVN.SW$285B+11%-4%30%17.5×1.6%
Pfizer PFE$160B+9%+1%26%9.9×-4.3%
Merck & MRK$340B+23%+5%18%16.4×8.3%
Danaher DHR$161B+34%+6%21%25.1×20.8%

How Roche compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Roche against its 13 peers (data as of 18 Nov 2026)
MeasureRO.SWPeer medianRank in peer set
1-month return+3.0%+3.9%6th lowest of 14
6-month return+21.2%+13.0%6th highest of 14
Distance from 52-week high-2.4%-6.3%highest of 14
Revenue growth (TTM)-1.1%+5.7%2nd lowest of 14
Operating margin30.6%30.4%6th highest of 14
Forward P/E19.9×16.4×4th most expensive of 14
Growth the price implies (Req g, 7 yrs)1.7%-0.1%6th most demanding of 14
Growth delivered (Del g)+1.1%+8.5%3rd lowest of 14
Hurdle (Req g minus delivered)+0.6 pp-8.0 pp4th most demanding of 14
ROIC minus cost of capital+18.4 pp+10.5 pp4th highest of 14
EV / EBITDA15.7×15.5×7th most expensive of 14
Net debt / EBITDA1.0×1.2×7th least indebted of 14
Bond spread62 bp67 bp6th tightest of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Roche RO.SWSwitzerland$381B+21%-1%31%19.9×1.7%+1.1%
Merck & MRKUnited States$340B+23%+5%18%16.4×8.3%+9.3%
AbbVie ABBVUnited States$506B+35%+11%36%18.1×-0.1%+6.0%
Novartis NOVN.SWSwitzerland$285B+11%-4%30%17.5×1.6%-0.2%
AstraZeneca AZN.LUnited Kingdom$278B-2%+5%23%17.6×14.4%+15.7%
Johnson & Johnson JNJUnited States$656B+20%+8%26%24.2×3.7%+2.7%
Novo Nordisk A/S NOVO-B.CODenmark$177B-6%+6%48%11.8×-0.5%+19.5%
Pfizer PFEUnited States$160B+9%+1%26%9.9×-4.3%+8.5%
Vertex Pharmaceuticals VRTXUnited States$136B+25%+11%35%28.5×6.2%+14.2%
Bristol Myers Squibb BMYUnited States$122B+3%+4%33%9.2×-13.1%+2.5%
Sanofi SAN.PAFrance$114B+13%+15%27%9.7×-4.8%+3.9%
Lilly (Eli) LLYUnited States$1.30T+36%+46%51%29.5×6.5%+21.6%
GSK GSK.LUnited Kingdom$97.9B-3%+4%25%10.4×-0.1%-0.9%
Regeneron Pharmaceuticals REGNUnited States$97.8B+46%+19%30%11.8×-1.1%+11.0%

Roche bonds and credit

Roche has 20 bonds outstanding with $17.9B face value. The agencies rate it AA; its bonds trade like AA. Weighted yield 5.03%, a spread of 62 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Roche's main competitors?
Named competitors: Novartis (NOVN.SW), Pfizer (PFE), Merck & Co (MRK), Danaher (DHR). The cockpit's measured peer set (industry) also includes Merck & (MRK), AbbVie (ABBV), Novartis (NOVN.SW), AstraZeneca (AZN.L), Johnson & Johnson (JNJ), Novo Nordisk A/S (NOVO-B.CO).
Is Roche expensive compared with its peers?
On forward p/e it trades at 19.9× against a peer median of 16.4×, 4th most expensive of 14 in its peer set. For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Roche stock performed?
Over six months to 18 Nov 2026 the shares returned +21.2% against +13.0% for the median peer; over one year +35.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.